Although hypophysitis is another well-recognized endocrine irAE, its incidence is much lower with PD-1/PD-L1 blockade compared with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, and when it occurs, it usually presents as central adrenal insufficiency with low or inappropriately normal TSH and FT4 [14,15]. Here, CTLA4 is linked to hypophysitis.